Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Cannon

Showing results (631-640 of 934) with videos related to

Pageof 94
Sort By:
Heart (British Cardiac Society)|June 25, 2014
Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromesChristoph Varenhorst, Ulrica Alström, Oscar Ö Braun, et al.
Circulation. Cardiovascular Quality and Outcomes|September 6, 2012
Guideline adherence after ST-segment elevation versus non-ST segment elevation myocardial infarctionKeith A Somma, Deepak L Bhatt, Gregg C Fonarow, et al.
Journal of the American College of Cardiology|April 23, 2003
Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18David A Morrow, James A de Lemos, Marc S Sabatine, et al.
JAMA Cardiology|March 15, 2017
Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol : A Prespecified Analysis of the IMPROVE-IT TrialRobert P Giugliano, Stephen D Wiviott, Michael A Blazing, et al.
Journal of the American College of Cardiology|June 19, 2024
Randomized Trial of a Vascular Care Team vs Education for Patients With Peripheral Artery DiseaseConnie N Hess, Ashley Daffron, Mark R Nehler, et al.
Platelets|October 17, 2013
Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO studyRobert F Storey, Stefan K James, Agneta Siegbahn, et al.
Journal of the American College of Cardiology|October 18, 2005
Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trialKausik K Ray, Christopher P Cannon, Richard Cairns, et al.
Stroke|April 20, 2021
Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-AnalysisZien Zhou, Meg J Jardine, Qiang Li, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|December 1, 2020
Antithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCIFrancesco Costa, Marco Valgimigli, Philippe Gabriel Steg, et al.
Circulation. Cardiovascular Quality and Outcomes|May 17, 2017
Impact of Ezetimibe on the Rate of Cardiovascular-Related Hospitalizations and Associated Costs Among Patients With a Recent Acute Coronary Syndrome: Results From the IMPROVE-IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)Yashashwi Pokharel, Khaja Chinnakondepalli, Katherine Vilain, et al.
Pageof 94

Showing results (631-640 of 934) with videos related to

Sort By:
Pageof 94
Heart (British Cardiac Society)|June 25, 2014
Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromesChristoph Varenhorst, Ulrica Alström, Oscar Ö Braun, et al.
Circulation. Cardiovascular Quality and Outcomes|September 6, 2012
Guideline adherence after ST-segment elevation versus non-ST segment elevation myocardial infarctionKeith A Somma, Deepak L Bhatt, Gregg C Fonarow, et al.
Journal of the American College of Cardiology|April 23, 2003
Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18David A Morrow, James A de Lemos, Marc S Sabatine, et al.
JAMA Cardiology|March 15, 2017
Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol : A Prespecified Analysis of the IMPROVE-IT TrialRobert P Giugliano, Stephen D Wiviott, Michael A Blazing, et al.
Journal of the American College of Cardiology|June 19, 2024
Randomized Trial of a Vascular Care Team vs Education for Patients With Peripheral Artery DiseaseConnie N Hess, Ashley Daffron, Mark R Nehler, et al.
Platelets|October 17, 2013
Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO studyRobert F Storey, Stefan K James, Agneta Siegbahn, et al.
Journal of the American College of Cardiology|October 18, 2005
Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trialKausik K Ray, Christopher P Cannon, Richard Cairns, et al.
Stroke|April 20, 2021
Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-AnalysisZien Zhou, Meg J Jardine, Qiang Li, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|December 1, 2020
Antithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCIFrancesco Costa, Marco Valgimigli, Philippe Gabriel Steg, et al.
Circulation. Cardiovascular Quality and Outcomes|May 17, 2017
Impact of Ezetimibe on the Rate of Cardiovascular-Related Hospitalizations and Associated Costs Among Patients With a Recent Acute Coronary Syndrome: Results From the IMPROVE-IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)Yashashwi Pokharel, Khaja Chinnakondepalli, Katherine Vilain, et al.
Pageof 94